Nuwellis, Inc.
NUWEHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeNuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. With a market capitalization of $2.5M, it sits in micro-cap territory. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients.
Market Cap
$2.5M
Beta
0.23
P/E (TTM)
0.00
P/E (Fwd)
-0.30
EPS (TTM)
$2548.34
EPS (Fwd)
$-2.59
ROE
—
ROA
-87.8%
Cash
$3.9M
Total Debt
$200,000
Free CF
-$11.4M
52W Change
-99.5%
Annual Financials
Cash vs Debt
Where NUWE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NUWE finished 97.53% below its 150-day moving average ($29.99) and 98.25% below its 200-day moving average ($42.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NUWE overbought or oversold?
At the September 3, 2026 close, NUWE's RSI(14) was 13.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.9M in cash comfortably exceeding the $200K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$11.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $8.5M (2022) to $8.3M (2025).
NUWE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, NUWE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NUWE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.